Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6BO7R)

• Drug Name: SUN-9221 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 85065607
  TTD Drug ID: DM6BO7R

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Benign prostatic hyperplasia	GA90	Approved	[3]
Armodafinil	DMGB035	Malignant glioma	2A00.0	Approved	[4]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[5]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[6]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[7]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[8]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[9]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[10]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[11]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[12]

Drug(s) Targeting 5-HT 2 receptor (5HT2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[13]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[14]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[15]
Ketanserin	DMVLMW6	Hypertension	BA00-BA04	Approved	[16]
Bis(olanzapine) pamoate monohydrate	DME76AP	Psychotic disorder	6A20-6A25	Phase 3	[17]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[18]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[19]
TGWOOAA	DMI57ZA	Generalized anxiety disorder	6B00	Phase 2	[20]
TGOF02N	DMQ6ANE	Schizophrenia	6A20	Phase 2	[21]
AMAP-102	DM7CD8Z	Arthritis	FA20	Phase 1	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Modulator	[2]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006767)
• [2] Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56.
• [3] The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
• [4] Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
• [5] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [6] Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
• [7] Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
• [8] Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
• [9] The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
• [10] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [11] Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
• [12] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [13] 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
• [14] Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
• [15] Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
• [16] Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [20] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [21] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [22] Clinical pipeline report, company report or official report of Anamar.